|
- Merck Gets FDA Approval For New HIV Treatment - Isentress
was approved as part of the
FDA's accelerated-approval mechanism, which is aimed at getting life-saving
treatments to market
faster by allowing companies to submit less clinical data than usually
required. Companies
obtaining accelerated approval must keep studying drugs after they are
on the market to gain full
approval. Click here to
view the PDF.
- New HIV Drug Update- Sept 2007- Clinical Care Options
Click here to view the PDF.
- Clinical trials of new antiretroviral drugs in highly
experienced patients also
show high rates of HIV-RNA suppression below 50 copies/ml.HIV-RNA
suppression below 50 copies/ml should now become the standard efficacy
endpoint across trials of both naive and experienced patients.
By Andrew Hill; Diego Miralles; Tony Vangeneugden; Eric Lefebvre
Click here to view the PDF.
- New medications, Salvage Therapy and treatment strategy.
A treatment manual for HIV infected patients with drug resistance.
By Dr. Paul C. Bellman
Click here
to view the PDF.
- A new approach for 'deep salvage' trials in advanced HIV
infection -
One of the most difficult problems in HIV care today is the management
of individuals
infected with multidrug-resistant viruses. Well-controlled, carefully
designed clinical trials
have recently resulted in the approval of several new antiviral agents
for the treatment of
drug-resistant HIV. Click here to view
the PDF.
- "This is the Forum for Collaborative Research's report from an
FDA/FCHR Joint Public Meeting entitled, Collaborative
Approaches to HIV Drug Development: Planning for Long-Term Monitoring
of Safety in CCR5 Antagonist Development.
This report is available in PDF format at http://www.hivforum.org/uploads/.pdf.
Presentations and other information
associated with this project are available at http://www.hivforum.org/projects/CCR5.htm.
- NATAPE-Resist 50 RNA Reduces Death Risk 83% in MDR
5th European HIV Drug Resistance
Workshop
Cascais, Portugal, March 30, 2007
- Do
not do as I did: Three
men tell their story in a new era of HIV treatment.
Please read the article
written by Enid Vazquez in the latest Positively Aware
Click here
- Emerging Drugs
Show Promise Against HIV Click
here.
- Rethinking
the Approach to Expanded Access Programs:
Background, Objectives, and Status Click here.
- Drug
Development Strategies for Salvage Therapy:
Conflicts and Solutions
-
Seeking Ethical Designs for HIV Clinical Trials in Treatment-
Experienced Patients: An Industry Perspective
-
Uncertain Future for Early Access?
thebody.com , January 2006
- New Antiretrovirals
for the Treatment of HIV: The View in 2006
- FDA Proposes Rules Overhaul to
Expand Availability of Experimental Drugs
- FDA Aims to Expand Access To Experimental
Drugs
- NATAP
Integrase Inhibitor Shows Strength in Treatment
Experienced
46tn ICAAC, September 27-30, 2006, San Francisco
Mark Mascolini
Sept 29, 2006
- AIDS
InfoNet - SALVAGE THERAPY
- ACRIA
update on new treatments
- Development
of DFC, an Investigational NRTI, Is Discontinued
-
HIV Antiretroviral Agents in Development by Edwin DeJesus, M.D. from
The Body Pro
- High
hopes for AIDS research - Experimental treatment fortifies the body's
own stem cells with an enzyme that may block the relentless advance
of the virus
- Expert Analysis - Investigational
Antiretrovirals - from Clinicaloptions.com
- POZ
- Simply Irresistible- by Nelson Vergel - May #123
- Encouraging
Data at 13th CROI on Novel New HIV Protease Inhibitor TMC 114 and Unique
Non Nucleoside TMC 125
- Research Principles
for Clinical Studies Using Volunteers with Three Drug Class Resistant
(3-DCR) HIV
- NATAP: 9% of Patients
with Multi-Drug Resistant HIV Died Within 2 Years
- Transcript
of The Body's Live Chat With Nelson Vergel on Issues for HIVers With
Multi-Drug Resistance
- POZ.COM
Entry Inhibitor Information
Nov 2004
- EUROPEAN ACTIVIST POSITION
ON SALVAGE ACCESS
- Tipranavir-New
Protease Inhibitor- for Resistance: 24-week results
Reported by Jules Levin, 44th ICAAC October 30-November 2, 2004
-
Emerging New Strategies for the Management of Treatment-Experienced
and Salvage Therapy Patients
- Codevelopment of new antiretrovirals
in very treatment-experienced HIV-infected individuals
Lancet. 2004 Sep 18;364(9439):1036-7
- NATAP REPORT
ON NEW HIV DRUGS & ENTRY INHIBITORS
-
GENOPHAR: A Randomized Study of Plasma Drug Measurements
- First CCR5
inhibitor to enter Phase III
from NATAP.ORG
- Bulletin
of Experimental Treatments for AIDS
Winter 2002/2003, Salvage Therapy, By Simon Collins
- FDA
Discusses Trial Design for Salvage Therapy
April 2001, From the Treatment Action Group (TAG), Volume 7, Issue 12
- Entry
Inhibitors
July 2004, Project Inform Perspective,
-
Anti-HIV Candidates in the Pipeline
Winter 2002/2003, ACRIA Update, Vol. 12, No. 1, By Liz Highleyman
- What
is the most important information I should know about tipranavir?
AIDS MEDS.COM
|
